Ceftaroline fosamil: a guide to its use in complicated skin and soft tissue infections and community-acquired pneumonia in the EU

被引：0

作者：

Scott L.J. ^{[1
]}

Frampton J.E. ^{[1
]}

机构：

[1] Springer, Private Bag 65901, Mairangi Bay, North Shore, Auckland

来源：

Drugs & Therapy Perspectives | 2015年 / 31卷 / 1期

关键词：

Ceftriaxone; Daptomycin; Clinical Success Rate; Clinical Cure Rate; Ceftaroline;

D O I：

10.1007/s40267-014-0174-9

中图分类号：

学科分类号：

摘要：

Ceftaroline fosamil (Zinforo™; Teflaro®), the prodrug of ceftaroline, is an advanced-generation, parenteral cephalosporin with a broad spectrum of activity against clinically relevant Gram-positive and Gram-negative organisms. In clinical trials, intravenous ceftaroline fosamil was an effective and generally well tolerated treatment in hospitalized patients with complicated skin and soft tissue infections (noninferior to intravenous vancomycin plus aztreonam) or hospitalized community-acquired pneumonia (superior to intravenous ceftriaxone). © 2014, Springer International Publishing Switzerland.

引用

页码：9 / 16

页数：7

共 50 条

[21] Critical appraisal of ceftaroline in the management of community-acquired bacterial pneumonia and skin infections
Goodman, Julian J.
Martin, Stanley I.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2012, 8 : 149 - 156
[22] Ceftaroline fosamil as a potential treatment option for Staphylococcus aureus community-acquired pneumonia in adults
Welte, Tobias
Kantecki, Michal
Stone, Gregory G.
Hammond, Jennifer
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2019, 54 (04) : 410 - 422
[23] Ceftaroline Fosamil For The Treatment Of Community-Acquired Bacterial Pneumonia In The Elderly: Capture Study Experience
Udeani, G.
Evans, J.
Cole, P.
Smith, A.
Friedland, H. D.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 189
[24] Pharmacokinetic/pharmacodynamic analysis to evaluate ceftaroline fosamil dosing regimens for the treatment of community-acquired bacterial pneumonia and complicated skin and skin-structure infections in patients with normal and impaired renal function
Canut, A.
Isla, A.
Rodriguez-Gascon, A.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2015, 45 (04) : 399 - 405
[25] Ceftobiprole medocaril: A guide to its use in hospital- or community-acquired pneumonia in the EU
Syed Y.Y.
Drugs & Therapy Perspectives, 2015, 31 (5) : 150 - 156
[26] A Retrospective Analysis of Probability of Target Attainment in Community-Acquired Pneumonia: Ceftaroline Fosamil Versus Comparators
Andrew Cristinacce
James G. Wright
Gregory G. Stone
Jennifer Hammond
Lynn McFadyen
Susan Raber
Infectious Diseases and Therapy, 2019, 8 : 185 - 198
[27] A Retrospective Analysis of Probability of Target Attainment in Community-Acquired Pneumonia: Ceftaroline Fosamil Versus Comparators
Cristinacce, Andrew
Wright, James G.
Stone, Gregory G.
Hammond, Jennifer
McFadyen, Lynn
Raber, Susan
INFECTIOUS DISEASES AND THERAPY, 2019, 8 (02) : 185 - 198
[28] Pharmacokinetic-Pharmacodynamic Analyses for Efficacy of Ceftaroline Fosamil in Patients with Community-Acquired Bacterial Pneumonia
Bhavnani, Sujata M.
Hammel, Jeffrey P.
Van Wart, Scott A.
Rubino, Christopher M.
Reynolds, Daniel K.
Forrest, Alan
Khariton, Tatiana
Friedland, H. David
Riccobene, Todd A.
Ambrose, Paul G.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (12) : 6348 - 6350
[29] Ceftaroline fosamil treatment outcomes compared with standard of care among hospitalized patients with complicated skin and soft tissue infections
Karve, Sudeep
Hackett, Judith
Levinson, Jeremy
Gibson, Edward
Battersby, Alysia
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2016, 5 (04) : 393 - 405
[30] Population Pharmacokinetics of Ceftaroline in Patients With Acute Bacterial Skin and Skin Structure Infections or Community-Acquired Bacterial Pneumonia
Van Wart, Scott A.
Forrest, Alan
Khariton, Tatiana
Rubino, Christopher M.
Bhavnani, Sujata M.
Reynolds, Daniel K.
Riccobene, Todd
Ambrose, Paul G.
JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 53 (11): : 1155 - 1167

← 1 2 3 4 5 →